Gemini Therapeutics

$2.92 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Gemini Therapeutics

Gemini Therapeutics, Inc. operates as a precision medicine company. The Company focuses on dry macular degeneration which is a disease comprised of numerous genetic variants. Gemini Therapeutics serves customers worldwide.

Stock Analysis

last close $3.1
1-mo return -11.9%
3-mo return -15.1%
avg daily vol. 116.48T
52-week high 19.09
52-week low 2.9
market cap. $139M
forward pe -
annual div. -
roe -42.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 71.9%
baraka

Subscribe now for daily local and international financial news

Subscribe